$XBIO
Xenetic Biosciences, Inc.

2024 Q1 Form 10-K Financial Statement

#000168316824001594 Filed on March 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $510.8K $672.0K $2.540M
YoY Change -15.69% 37.99% 48.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $834.9K $952.0K $3.561M
YoY Change -9.81% 11.06% -2.55%
% of Gross Profit
Research & Development $944.3K $975.6K $3.495M
YoY Change 58.64% -18.23% -26.75%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.779M $1.928M $7.056M
YoY Change 16.98% -5.98% -16.25%
Operating Profit -$1.268M -$4.516M
YoY Change 38.6% -32.78%
Interest Expense $73.25K $83.76K $355.8K
YoY Change 35.4% 4.95% 112.84%
% of Operating Profit
Other Income/Expense, Net $73.30K $400.00 $381.1K
YoY Change 25.04% -59.6% 130.22%
Pretax Income -$1.195M -$1.172M -$4.135M
YoY Change 39.53% -20.98% -36.9%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.195M -$1.172M -$4.135M
YoY Change 39.53% -20.98% -36.9%
Net Earnings / Revenue -233.96% -174.34% -162.78%
Basic Earnings Per Share -$0.78 -$2.71
Diluted Earnings Per Share -$0.78 -$0.76 -$2.71
COMMON SHARES
Basic Shares Outstanding 1.541M shares 1.541M shares 1.528M shares
Diluted Shares Outstanding 1.541M shares 1.528M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.824M $8.983M $8.983M
YoY Change -34.77% -31.41% -31.41%
Cash & Equivalents $7.824M $8.983M
Short-Term Investments
Other Short-Term Assets $552.0K $603.8K $603.8K
YoY Change -37.02% 8.58% 8.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.376M $9.587M $9.587M
YoY Change -34.93% -29.78% -29.78%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.018M $1.018M $1.018M
YoY Change 20.6% -4.55% -4.55%
Total Long-Term Assets $1.018M $1.018M $1.018M
YoY Change 20.6% -4.55% -4.55%
TOTAL ASSETS
Total Short-Term Assets $8.376M $9.587M $9.587M
Total Long-Term Assets $1.018M $1.018M $1.018M
Total Assets $9.394M $10.61M $10.61M
YoY Change -31.51% -27.96% -27.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $210.5K $240.8K $240.8K
YoY Change -18.79% -16.19% -16.19%
Accrued Expenses $506.0K $568.8K $568.8K
YoY Change -15.27% -27.62% -27.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $716.5K $809.6K $809.6K
YoY Change -16.33% -24.56% -24.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $716.5K $809.6K $809.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $716.5K $809.6K $809.6K
YoY Change -16.33% -24.56% -24.56%
SHAREHOLDERS EQUITY
Retained Earnings -$194.4M -$193.2M
YoY Change 2.35% 2.19%
Common Stock $1.544K $1.544K
YoY Change -89.84% -89.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.678M $9.796M $9.796M
YoY Change
Total Liabilities & Shareholders Equity $9.394M $10.61M $10.61M
YoY Change -31.51% -27.96% -27.96%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$1.195M -$1.172M -$4.135M
YoY Change 39.53% -20.98% -36.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.159M -$794.2K -$4.114M
YoY Change 5.16% 5.77% -11.46%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$1.159M -794.2K -$4.114M
Cash From Investing Activities 0.000 $0.00
Cash From Financing Activities
Net Change In Cash -$1.159M -794.2K -$4.114M
YoY Change 5.16% 5.77% -20.06%
FREE CASH FLOW
Cash From Operating Activities -$1.159M -$794.2K -$4.114M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$794.2K -$4.114M
YoY Change 5.77% -20.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001534525
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022 xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
CY2023 xbio Issuance Of Common Stock To Adjust For Reverse Split Rounding
IssuanceOfCommonStockToAdjustForReverseSplitRounding
usd
CY2023 xbio Conversion Of Series Preferred Stock To Shares Of Common Stock
ConversionOfSeriesPreferredStockToSharesOfCommonStock
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37937
CY2023 dei Entity Registrant Name
EntityRegistrantName
XENETIC BIOSCIENCES, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2952962
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
945 Concord Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Framingham
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01701
CY2023 dei City Area Code
CityAreaCode
781
CY2023 dei Local Phone Number
LocalPhoneNumber
778-7720
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
5026928 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1540684 shares
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2023Q4 us-gaap Cash
Cash
8983046 usd
CY2022Q4 us-gaap Cash
Cash
13097265 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
603828 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
556094 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9586874 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13653359 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1018352 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1066931 usd
CY2023Q4 us-gaap Assets
Assets
10605226 usd
CY2022Q4 us-gaap Assets
Assets
14720290 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
240832 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287360 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
568753 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
785796 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
809585 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1073156 usd
CY2023Q4 us-gaap Liabilities
Liabilities
809585 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1073156 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1543385 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1519360 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1540684 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1516659 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1544 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1520 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208053935 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207769904 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193234196 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189099618 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9795641 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10605226 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14720290 usd
CY2023 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
2539986 usd
CY2022 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1706925 usd
CY2023 us-gaap Revenues
Revenues
2539986 usd
CY2022 us-gaap Revenues
Revenues
1706925 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3494765 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4770834 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3560936 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3653999 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
7055701 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
8424833 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-4515715 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-6717908 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25380 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1597 usd
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
355757 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
167152 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
381137 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
165555 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-4134578 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6552353 usd
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1528210 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1528210 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18394257 usd
CY2022 xbio Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
1293750 shares
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
511480 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6552353 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
283085 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-4134578 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9795641 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-4134578 usd
CY2023 xbio Research And Developments In Process
ResearchAndDevelopmentsInProcess
0 usd
CY2022 xbio Research And Developments In Process
ResearchAndDevelopmentsInProcess
1793750 usd
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
27043 usd
CY2023 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
283085 usd
CY2022 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
511480 usd
CY2023 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
47734 usd
CY2022 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
103738 usd
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-48579 usd
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-25000 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-263571 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-347947 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4114219 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4646765 usd
CY2023 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
-0 usd
CY2022 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
500000 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-500000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4114219 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5146765 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13097265 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18244030 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8983046 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13097265 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023 xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
0 usd
CY2022 xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
1293750 usd
CY2023 xbio Issuance Of Common Stock To Adjust For Reverse Stock Split
IssuanceOfCommonStockToAdjustForReverseStockSplit
16 usd
CY2022 xbio Issuance Of Common Stock To Adjust For Reverse Stock Split
IssuanceOfCommonStockToAdjustForReverseStockSplit
0 usd
CY2023 xbio Conversion Of Series Preferred Stock To Common Stock
ConversionOfSeriesPreferredStockToCommonStock
970 usd
CY2022 xbio Conversion Of Series Preferred Stock To Common Stock
ConversionOfSeriesPreferredStockToCommonStock
0 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_z0wTX4DRA9fk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_z8JcDS012DC4">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenue, costs and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes may differ materially from management’s estimates, judgments and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zJjJJ3uIKDjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86D_zDHgs9Hz3iKh">Cash and Concentrations of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Investments with original maturities of greater than 90 days from the date of purchase but less than one year from the balance sheet date are classified as short-term investments, while investments with maturities of one year or beyond from the balance sheet date are classified as long-term investments. Management determines the appropriate classification of its cash equivalents and investment securities at the time of purchase and re-evaluates such determination as of each balance sheet date. The carrying amount of cash equivalents approximate their fair value due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to credit risk consist primarily of cash on deposit with financial institutions, the balances of which may exceed federally insured limits. The Company has not experienced any losses on such accounts, and does not believe it is exposed to any unusual credit risk beyond the normal credit risk currently associated with commercial banking relationships. The Company maintains its primary banking relationship with one large financial institution and all cash on deposit is covered under federally insured limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5000 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5000 shares
CY2023Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
78000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
400000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
216547 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
353539 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
233950 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
288808 usd
CY2023Q4 xbio Accrued Research Costs
AccruedResearchCosts
70000 usd
CY2022Q4 xbio Accrued Research Costs
AccruedResearchCosts
103500 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
48256 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39949 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
568753 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
785796 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-4134578 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6552353 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-868261 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-1375995 usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-373684 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-476802 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1116036 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7233525 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
271546 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
197151 usd
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
81227 usd
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-39041 usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
7213 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
19087 usd
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
238631 usd
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
109792 usd
CY2023 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 usd
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-5120196 usd
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
4554 usd
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-327937 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
6573614 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
6085858 usd
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
8066098 usd
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
8546593 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2235214 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2169480 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2038421 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1820269 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1473049 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
735702 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
2142380 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
1913128 usd
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
250669 usd
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
288887 usd
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
39707112 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38569096 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39707112 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38569096 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
0 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
0 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0 usd
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0 usd
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0 usd
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 usd
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
500000 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
283085 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
511480 usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
0 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
27043 usd
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-001594-index-headers.html Edgar Link pending
0001683168-24-001594-index.html Edgar Link pending
0001683168-24-001594.txt Edgar Link pending
0001683168-24-001594-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbio-20231231.xsd Edgar Link pending
xenetic_ex0401.htm Edgar Link pending
xenetic_ex2101.htm Edgar Link pending
xenetic_ex2301.htm Edgar Link pending
xenetic_ex3101.htm Edgar Link pending
xenetic_ex3102.htm Edgar Link pending
xenetic_ex3201.htm Edgar Link pending
xbio-20231231_def.xml Edgar Link unprocessable
xbio-20231231_pre.xml Edgar Link unprocessable
xenetic_ex9701.htm Edgar Link pending
xenetic_i10k-123123.htm Edgar Link pending
xbio-20231231_cal.xml Edgar Link unprocessable
xbio-20231231_lab.xml Edgar Link unprocessable
xenetic_i10k-123123_htm.xml Edgar Link completed